B

BioXcel Therapeutics

D
BTAI
USD
-0.1224
(-19.5091%)
Market Closed
2,996.00
حجم التداول
-1.89
الربح لكل سهم
-
العائد الربحي
-0.154798
P/E
20,575,599.81
حجم السوق
اليوم
-19.5091%
1 اسبوع
-25.185%
1 شهر
-6.429%
6 اشهر
-76.179%
12 اشهر
-88.019%
بداية السنة
-82.939%
كل الوقت
-95.039%
avatar
sara abdelazim
عدد النقاط
112
عدد التوصيات
2

Title:
BioXcel Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
هل تحتاج مساعدة او لديك استفسار؟